Ion Channel Technologies
The importance of drug safety issues in the pharmaceutical industry has created a need for increased high-throughput drug screening for ion channel sensitivity early in the drug discovery process. For instance, drug-induced QT-prolongation and cardiac arrhythmias have resulted in the emergence of the S7B and E14 guidance documents for drug safety assessment. Early detection of such risks helps direct focus towards potentially marketable drugs and prevents the investment of time and resources in drugs which will not pass the rigorous testing required for approval. New technologies and resources for high-throughput screening during early drug discovery phases continue to revolutionize the marketplace and promise to decrease bottlenecks while increasing output. As drugs go off-patent and pharmaceutical companies strive to find novel therapeutic solutions, automation of high-throughput drug screening equipment will continue to lower costs and improve efficacy and drug safety.
Category Press Releases